

Domperidone 10 mg

Orodispersible Tablet



Orodispersible facilitates oral intake and improves patients' compliance

Key features


- Firstline treatment of nausea and vomiting acting with lower potential to induce dystonic, extrapyramidal symptoms or galactorrhoea.
- Orodispersible tablet formulation facilitating water-free intake by oral route in patients suffering from nausea and vomiting or who have difficulties in swallowing.

Competitive advantages

- Selective D2/D3 dopamine antagonist.
- Combine prokinetic and anti-emetic activities on gastrointestinal tract making it an ideal agent for treating gastroparesis (postprandial fullness, nausea, vomiting and stomach fullness). Does not cross the blood-brain barrier minimizing CNS adverse events.

Regulatory status

- INN: Domperidone
- ATC Code: A03FA03
- CAS registry number 57808-66-9
- Reference compound: MOTILIUM[®], Janssen.
- BioEq. study
 - Patient population: 36 male & female healthy volunteers.
 - Methodology: Randomized two-way crossover.
 - Reference product: MOTILIUM[®] instant 10 mg, J&J Belgium.
- Zone IV stability data available.
- CTD dossier available.
- Marketed in Europe & Emerging markets.



Domperidone 10 mg

Oro-Dispersible Tablet

ANTI-EMETIC / ONCOLOGY

Information at a glance

- Commercial batch size (million doses): 0.5
- Dossier Batch size (million doses): 0.5
- Shelf-life: 3 years
- Storage conditions: Room temperature between 20 and 25°C
- Pack info: Aluminium 10-tabs blister & pack
- Tablet weight: 250 mg
- Flavour: Trusil peppermint

Market highlights

- The global nausea and vomiting treatment market size is projected to reach \$7,214 million by 2026 from \$4,947 in 2020 at a CAGR of 6.5% from 2021 to 2026¹.
- The global chemotherapy-induced nausea and vomiting market is valued \$1,663 million in 2015 to reach \$2,659 million by 2022 at a CAGR of 7,1% from 2016-2022. According to the US National Cancer Institute chemotherapy-induced nausea and vomiting occurs in up to 80% of patients^{2,3}.

Competitors' landscape

- Neuroleptic derivatives (PRIMPERAN®/metoclopramide, VOGALENE®/metopimazine, PHENERGAN®/promethazine, etc.), 5-HT₃ receptor antagonists, neurokinin NK₁ antagonists.

REFERENCES

1. Global Nausea & vomiting treatment market report; Market Reports World
2. Global Chemotherapy-induced Nausea & Vomiting Market; Allied Market Research
3. US National Cancer Institute, Physician Data Query (PDQ) Summary

Disclaimer: Athena if performed, will make available to potential customers its own IP assessment. Potential customers may on the basis thereof make their own independent assessment with respect to the absence of the violation of any intellectual property rights of any third party in the development and use of the regulatory dossier that could render unlawful the manufacture, import, marketing, sale, and/or distribution of the products in the relevant territory.



Key numbers

- 2026 Global Nausea & Vomiting market > \$7.2 billion
- Chemotherapy-induced nausea & vomiting occurs in up to 80% of patients
- 2022 Chemotherapy-induced nausea & vomiting market > \$2.6 billion

ASIA patil.amit@ddsathena.com

CANADA/USA hafid@tradepassrx.com

FRANCE francois.ribeaux@athenaips.com

GLOBAL hugues.benevent@athenaips.com
frederic.besancon@athenaips.com
awilliams@ddsathena.com

LATAM schauenberg.bruno@ddsathena.com

MENA patil.amit@ddsathena.com

OTHER contact@ddsathena.com